Department of Medical Sciences, University of Wisconsin-Madison School of Veterinary Medicine, Madison, Wisconsin, USA.
Department of Small Animal Clinical Sciences, University of Tennessee Knoxville College of Veterinary Medicine, Knoxville, Tennessee, USA.
J Vet Intern Med. 2023 Nov-Dec;37(6):2109-2118. doi: 10.1111/jvim.16886. Epub 2023 Sep 30.
Proton pump inhibitors can cause diarrhea and a transient increase in fecal dysbiosis index in dogs. It is unknown if concurrent probiotic administration mitigates these effects.
OBJECTIVE/HYPOTHESIS: To assess the fecal Canine Microbial Dysbiosis Index (CMDI), fecal short chain fatty acid (SCFA), and fecal calprotectin concentrations in dogs administered esomeprazole with and without a probiotic.
Eleven healthy dogs.
Prospective, within-subjects before and after study. All dogs received 7-day courses of esomeprazole (1 mg/kg PO q 24h) alone followed by esomeprazole with a probiotic (15 billion CFU/kg), separated by a 4-week washout period. Data were compared between phases using mixed effects ANOVA or generalized estimating equations with post-hoc Holm adjustment for 2-way comparisons.
Compared to baseline (mean CMDI -2.66, SD 3.04), fecal CMDI was not different with esomeprazole administration alone (mean CMDI -1.48, SD 3.32, P = .08), but there was a significant increase (Diff 3.05, 95% CI [1.37, 4.74], P < .001, Effect size 2.02) when esomeprazole and a probiotic were administered concurrently (mean CMDI 0.39, SD 2.83). CMDI was significantly higher when esomeprazole was administered with a probiotic than alone (Diff 1.87, 95% CI [0.19, 1.87], P = .02, Effect size 1.24). Fecal calprotectin and SCFA concentrations did not differ between phases. The occurrence of vomiting and diarrhea was not different from baseline when esomeprazole was administered alone (36%/27%) or with a probiotic (46%/9%).
In healthy dogs, concurrent administration of a probiotic is unlikely to lessen adverse effects associated with esomeprazole administration.
质子泵抑制剂可引起犬腹泻和粪便微生物失调指数短暂升高。目前尚不清楚同时给予益生菌是否可以减轻这些影响。
目的/假设:评估接受埃索美拉唑治疗和同时给予益生菌治疗的犬粪便犬微生物失调指数(CMDI)、粪便短链脂肪酸(SCFA)和粪便钙卫蛋白浓度。
11 只健康犬。
前瞻性、自身前后对照研究。所有犬均接受 7 天埃索美拉唑(1mg/kg PO q24h)单药治疗,然后间隔 4 周洗脱期后给予埃索美拉唑联合益生菌(150 亿 CFU/kg)。使用混合效应方差分析或广义估计方程比较各阶段数据,对于 2 种比较采用事后 Holm 调整的广义估计方程。
与基线相比(CMDI 平均值-2.66,SD 3.04),单独使用埃索美拉唑治疗时粪便 CMDI 无差异(CMDI 平均值-1.48,SD 3.32,P=0.08),但同时使用埃索美拉唑和益生菌时 CMDI 显著增加(差值 3.05,95%CI [1.37, 4.74],P<0.001,效应量 2.02)。与单独使用埃索美拉唑相比,同时使用埃索美拉唑和益生菌时 CMDI 显著升高(差值 1.87,95%CI [0.19, 1.87],P=0.02,效应量 1.24)。粪便钙卫蛋白和 SCFA 浓度在各阶段之间无差异。单独使用埃索美拉唑(36%/27%)或同时使用益生菌(46%/9%)时,呕吐和腹泻的发生率与基线相比无差异。
在健康犬中,同时给予益生菌不太可能减轻埃索美拉唑给药相关的不良反应。